Mostra i principali dati dell'item
Systemic sclerosis: From pathogenesis towards targeted immunotherapies
dc.creator | Sakkas, L. I. | en |
dc.creator | Chikanza, I. C. | en |
dc.creator | Platsoucas, C. D. | en |
dc.date.accessioned | 2015-11-23T10:46:49Z | |
dc.date.available | 2015-11-23T10:46:49Z | |
dc.date.issued | 2012 | |
dc.identifier | 10.2174/157339712801318920 | |
dc.identifier.issn | 15733971 | |
dc.identifier.uri | http://hdl.handle.net/11615/32795 | |
dc.description.abstract | Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur very early in the disease process, and inflammatory infiltrates in the skin are restricted in early-phase disease. There is good evidence that fibroblast activation with collagen production may be triggered by the immune system. In early-phase disease, we slowly move from general immunosuppression to therapeutically targeting specific molecules involved in immune activation, such as T cell-directed targets, B cell-directed targets, cytokine targets, and tyrosine kinases targets. © 2012 Bentham Science Publishers. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84870179518&partnerID=40&md5=bcd174e3b20dbc84d05411647384e87a | |
dc.subject | B cell | en |
dc.subject | Fibroblast | en |
dc.subject | Immune activation | en |
dc.subject | Immunotherapy | en |
dc.subject | Systemic sclerosis | en |
dc.subject | T cell | en |
dc.subject | Targeted therapy | en |
dc.subject | abatacept | en |
dc.subject | autoantibody | en |
dc.subject | basiliximab | en |
dc.subject | belimumab | en |
dc.subject | bleomycin | en |
dc.subject | bosentan | en |
dc.subject | CD20 antibody | en |
dc.subject | collagen | en |
dc.subject | collagen type 1 | en |
dc.subject | cyclophosphamide | en |
dc.subject | cyclosporin A | en |
dc.subject | cytokine | en |
dc.subject | dipeptidyl carboxypeptidase inhibitor | en |
dc.subject | endothelin receptor antagonist | en |
dc.subject | everolimus | en |
dc.subject | halofuginone | en |
dc.subject | imatinib | en |
dc.subject | immunoglobulin | en |
dc.subject | methotrexate | en |
dc.subject | monoclonal antibody | en |
dc.subject | monoclonal antibody IL13 | en |
dc.subject | monoclonal antibody TGFbeta1 | en |
dc.subject | mycophenolic acid 2 morpholinoethyl ester | en |
dc.subject | protein tyrosine kinase | en |
dc.subject | rapamycin | en |
dc.subject | recombinant gamma interferon | en |
dc.subject | rituximab | en |
dc.subject | thymocyte antibody | en |
dc.subject | tocilizumab | en |
dc.subject | unclassified drug | en |
dc.subject | unindexed drug | en |
dc.subject | alopecia | en |
dc.subject | antibody production | en |
dc.subject | article | en |
dc.subject | autologous hematopoietic stem cell transplantation | en |
dc.subject | B lymphocyte | en |
dc.subject | chronic graft versus host disease | en |
dc.subject | chronic myeloid leukemia | en |
dc.subject | diarrhea | en |
dc.subject | disease course | en |
dc.subject | drug mechanism | en |
dc.subject | drug megadose | en |
dc.subject | drug targeting | en |
dc.subject | fatigue | en |
dc.subject | finger ulcer | en |
dc.subject | fluid retention | en |
dc.subject | gastrointestinal tumor | en |
dc.subject | graft versus host reaction | en |
dc.subject | human | en |
dc.subject | humoral immune deficiency | en |
dc.subject | hypertriglyceridemia | en |
dc.subject | immune system | en |
dc.subject | immunopathogenesis | en |
dc.subject | immunosuppressive treatment | en |
dc.subject | inflammatory infiltrate | en |
dc.subject | interstitial lung disease | en |
dc.subject | lung fibrosis | en |
dc.subject | lung function | en |
dc.subject | microangiopathy | en |
dc.subject | myalgia | en |
dc.subject | nonhuman | en |
dc.subject | nonmyeloablative stem cell transplantation | en |
dc.subject | priority journal | en |
dc.subject | pulmonary hypertension | en |
dc.subject | scleroderma | en |
dc.subject | side effect | en |
dc.subject | skin | en |
dc.subject | skin examination | en |
dc.subject | systemic lupus erythematosus | en |
dc.subject | T lymphocyte | en |
dc.subject | unspecified side effect | en |
dc.subject | whole body radiation | en |
dc.title | Systemic sclerosis: From pathogenesis towards targeted immunotherapies | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |